Skip to main content
TipRanks
Go Ultimate75% OFF

PMGC Holdings (ELAB) AI Stock Analysis

370 Followers
ELAB

PMGC Holdings

(NASDAQ:ELAB)

Select Model
Rating:39.7Underperform
Price Target:$1.50â–²(1.35% Upside)
Action:reiterated
Date:11/14/26

The overall score is very low, driven primarily by a precarious financial state characterized by deep losses, negative cash flow, and rising debt. This is compounded by a severely bearish technical trend, with the stock in a deep downtrend and showing no signs of momentum reversal. While recent corporate events show some strategic progress in securing non-dilutive cash and advancing pipeline programs, a key obesity study setback for EL-32 adds substantial risk, failing to offset the dominant financial and technical weaknesses.

Positive Factors
Revenue ReboundThe sharp TTM revenue rebound indicates renewed commercial activity and provides a larger base from which PMGC can develop its healthcare and pharmaceutical operations. If growth persists, greater scale could improve operating leverage and support future investment in products and acquisitions.
Negative Factors
Persistent UnprofitabilityVery low gross margin and substantial operating and net losses show that current revenue is not covering the cost base. This limits internally funded growth, increases dependence on financing or asset monetization, and raises execution risk until the business demonstrates sustainable operating leverage.

PMGC Holdings (ELAB) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%ELAB-99.87%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.34M
Dividend Yield
―
Average Volume (3M)
279.23K
Price to Earnings (P/E)
-0.0
Beta (1Y)
3.43
Revenue Growth
―
EPS Growth
―
Country
US
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

PMGC Holdings Business Overview & Revenue Model

Company Description

PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical...

PMGC Holdings Financial Statement Overview

Summary

Financial health is critically weak. While TTM revenue surged to $4.8M, the company is deeply unprofitable with a -209.5% EBIT margin and a $10.9M net loss. Cash flow is negative, with operating cash burn of $1.75M, and debt has rapidly increased to $11.9M, creating a precarious high-risk profile.

Income Statement

35Negative

Balance Sheet

55Neutral

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.82M590.08K2.47M0766.28K827
Gross Profit539.65K74.81K1.80M-554447.31K739
EBITDA-11.72M-7.27M-3.27M-1.13M-1.79M-781.98K
Net Income-13.30M-7.71M-6.25M-4.30M-1.80M-784.74K
Balance Sheet
Total Assets133.10M12.87M8.99M5.19M1.89M666.25K
Cash, Cash Equivalents and Short-Term Investments13.53M5.40M3.98M3.33M1.15M411.86K
Total Debt11.95M2.64M0210.49K283.22K0
Total Liabilities21.03M5.03M2.33M1.36M760.87K215.62K
Stockholders Equity12.11M7.84M6.66M3.83M1.13M450.63K
Cash Flow
Free Cash Flow-2.10M-6.38M-5.50M-4.57M-1.62M-693.42K
Operating Cash Flow-1.75M-5.93M-5.49M-4.56M-1.59M-660.93K
Investing Cash Flow-7.47M-2.77M-610.56K-11.19K-32.03K-32.48K
Financing Cash Flow122.15M10.12M6.76M6.74M2.36M1.09M

PMGC Holdings Technical Analysis

Technical Analysis SentimentNegative
Last Price1.48

Price Trends

50DMA3.19Negative
100DMA6.11Negative
200DMA24.32Negative

Market Momentum

MACD-0.52Negative
RSI23.20Positive
STOCH24.70Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Negative. The current price of 1.48 is below the 20-day moving average (MA) of 2.14, below the 50-day MA of 3.19, and below the 200-day MA of 24.32, indicating a bearish trend. The MACD of -0.52 indicates Negative momentum. The RSI at 23.20 is Positive, neither overbought nor oversold. The STOCH value of 24.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELAB.

PMGC Holdings Risk Analysis

PMGC Holdings disclosed 79 risk factors in its most recent earnings report. PMGC Holdings reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

PMGC Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ELAB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
INDPINDP47Neutral$529.93M-0.86-206.82%――87.31%
CNSPCNSP41Neutral$5.09M-0.18-166.03%――68.89%
BDRXBDRX40Underperform$1.17M-44.55-42.42%――97.97%
ELABELAB40Underperform$1.34M-0.00-107.91%―――

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%ELABBDRXINDPCNSPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ELAB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ELABPMGC Holdings Inc.1.48-1192.52-99.88%
BDRXBiodexa Pharmaceuticals Plc2.14-152.26-98.61%
INDPIndaptus Therapeutics, Inc.3.321.2560.39%
CNSPCns Pharmaceuticals, Inc.4.15-2.58-38.34%

PMGC Holdings Corporate Events

Product-Related Announcements

PMGC Reports Preliminary Results from EL-32 Obesity Study

Negative
Nov 5, 2026

On November 5, 2026, PMGC announced completion of an eight-week preclinical study evaluating EL-32 alone and with semaglutide in obese mice. The study examined body weight, body composition, glucose regulation and insulin sensitivity, and produced pr...

M&A TransactionsPrivate Placements and Financing

PMGC Holdings Agrees to Subscribe for Secured Debentures

Neutral
Nov 2, 2026

On October 30, 2026, PMGC Holdings Inc. agreed to subscribe for US$1.845 million of secured, non-interest-bearing debentures issued by Nuclea Energy Canada Inc. The financing was part of Nuclea Canada’s up-to-US$9 million offering, with proceeds desi...

Business Operations and StrategyRegulatory Filings and Compliance

PMGC Holdings Updates Investor Deck, Highlights Defense Strategy

Positive
Oct 28, 2026

On October 28, 2026, PMGC Holdings prepared an updated corporate slide deck and a separate maritime defense technology deck for use in investor and stakeholder presentations. The materials outline how the company is positioning its diversified portfo...

Business Operations and StrategyPrivate Placements and Financing

PMGC Secures Long-Term Royalty Cash Flow Agreement

Positive
Sep 18, 2026

On September 18, 2026, PMGC Holdings Inc. and its wholly owned subsidiary NorthStrive Biosciences Inc. entered into an interest-bearing payment agreement with Longevity Health Holdings, securing royalty payments from the January 2025 sale of the Elev...

Business Operations and Strategy

PMGC Holdings advances AI-driven cardiometabolic expansion program

Positive
Sep 2, 2026

On August 27, 2026, NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings, executed a First Amendment to its Development and License Agreement with Yuva Biosciences to formalize a three-phase Expansion Program for four AI-discovered sma...

Business Operations and StrategyStock BuybackPrivate Placements and Financing

PMGC Holdings Secures New Trademark License Agreement

Positive
Aug 27, 2026

On August 27, 2026, PMGC Holdings entered a five-year trademark license agreement with NorthStrive Companies Inc., gaining limited, royalty-free rights to use the NorthStrive brand and related marks for a nominal fee, tightening control over branding...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026